NDA 018631 · Validus Pharms
Trental
Pentoxifylline · Oral · Blood Viscosity Reducer
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 15, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Aug 30, 1984
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
180
42 Phase 3, 12 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Pentoxifylline" as an intervention, any sponsor and status, largest first.
- Pentoxifylline in Diabetic Kidney DiseasePivotal-lookingActive, not recruiting
VA Office of Research and DevelopmentFederal agency
NCT03625648 · 2,376 participants · Start Nov 18, 2019 · Primary completion Jan 3, 2028
Drug: Pentoxifylline; Placebo · For: Diabetic Kidney Disease
Sites: Phoenix, Arizona; Little Rock, Arkansas; Loma Linda, California · 34 sites in all
- Prostaglandin E1 in Outpatients With Intermittent ClaudicationPivotal-lookingCompleted
UCB PharmaUCB
NCT01263925 · 561 participants · Start Apr 2001 · Primary completion Apr 2011
Drug: Alprostadil (Prostaglandin E1); Pentoxifylline and 2 more · For: Stage II Peripheral Arterial Occlusive Disease; Intermittent Claudication Fontaine Stage II PAOD
Sites: Aachen, Germany; Bad Säckingen, Germany; Berlin, Germany · 36 sites in all
- RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative MedicinePivotal-lookingCompleted
University Health Network, TorontoAcademic, hospital or other
NCT05513560 · 460 participants · Start May 31, 2023 · Primary completion Mar 31, 2025
Drug: Ibudilast; Pentoxifylline · For: Long COVID; Post COVID Condition; Post Acute Sequelae of COVID-19
Sites: Ottawa, Canada; Toronto, Canada · 3 sites in all
- Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)Pivotal-lookingStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT01377285 · 350 participants (planned) · Start Jun 2010 · Primary completion Dec 2018
Drug: ARB; Pentoxifylline and 1 more · For: Chronic Renal Failure
Sites: Taipei, Taiwan
- Clinical Trial of Pentoxifylline in Patient With CirrhosisPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00162552 · 342 participants · Start Aug 2004 · Primary completion Dec 2007
Drug: pentoxifylline; PLACEBO · For: Cirrhosis; Liver Failure
Sites: Clichy, France
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06494111 · 295 participants (planned) · Start Feb 13, 2025 · Primary completion May 1, 2029
Drug: Pravastatin; Pentoxifylline and 1 more · For: Lymphedema; Fibrosis
Sites: Houston, Texas
- Double-blind Randomized Controlled Trial in Severe Alcoholic HepatitisPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT01214226 · 278 participants · Start Dec 2007 · Primary completion Dec 2010
Drug: Pentoxifylline; placebo · For: Alcoholic Hepatitis; Alcoholic Liver Disease
Sites: Brussels, Belgium; Angers, France; Béthune, France · 28 sites in all
- Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)Pivotal-lookingRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06912763 · 250 participants (planned) · Start Aug 8, 2025 · Primary completion Jul 31, 2030
Drug: Pravastatin (drug); Pentoxifylline and 3 more · For: Fibrosis Syndrome; Lymphedema; Head &Amp; Neck Cancer and 1 more
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prednisolone or pentoxifylline for alcoholic hepatitis.
Thursz MR, Richardson P, Allison M, et al. · N Engl J Med 2015 · Multicenter Study, Randomized Controlled Trial
- Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review.
Cavalcante RC, Tomasetti G · J Craniomaxillofac Surg 2020 · Systematic Review
- Pentoxifylline for endometriosis.
Lu D, Song H, Li Y, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pentoxifylline for intermittent claudication.
Broderick C, Forster R, Abdel-Hadi M, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cilostazol for intermittent claudication.
Brown T, Forster RB, Cleanthis M, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pentoxifylline for intermittent claudication.
Salhiyyah K, Forster R, Senanayake E, et al. · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Validus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.